These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 3627045)

  • 21. Continuous ambulatory peritoneal dialysis: three years' experience.
    Ramos JM; Gokal R; Siamopolous K; Ward MK; Wilkinson R; Kerr DN
    Q J Med; 1983; 52(206):165-86. PubMed ID: 6611839
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Aluminum absorption in the presence of normal kidney function: the effect of the pH].
    Olaizola Ottonello I; Serrano Arias M; Vizoso Piñeiro F; Rodrigo Saez L; García Morán M; Cannata Andía JB
    Rev Clin Esp; 1991 May; 188(9):442-5. PubMed ID: 1896590
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Can low-dosage aluminium hydroxide control the plasma phosphate without bone toxicity?
    Jenkins DA; Gouldesbrough D; Smith GD; Cowie JF; Winney RJ
    Nephrol Dial Transplant; 1989; 4(1):51-6. PubMed ID: 2494599
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Aluminum poisoning in dialysis patients--diagnosis and therapy].
    Vogelsang U
    Schweiz Rundsch Med Prax; 1994 Jun; 83(24):738-56. PubMed ID: 8023059
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma aluminium: a redundant test for patients on dialysis?
    Gault PM; Allen KR; Newton KE
    Ann Clin Biochem; 2005 Jan; 42(Pt 1):51-4. PubMed ID: 15802033
    [TBL] [Abstract][Full Text] [Related]  

  • 26. RenaGel efficacy in severe secondary hyperparathyroidism.
    Castro R; Herman A; Ferreira C; Travassos F; Nunes-Azevedo J; Oliveira M
    Nefrologia; 2002; 22(5):448-55. PubMed ID: 12497746
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effect of aluminium-hydroxide-containing antacids on the intestinal absorption of iron in patients on long-term dialysis].
    Blumberg A
    Schweiz Med Wochenschr; 1977 Jul; 107(30):1064-6. PubMed ID: 897649
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bullous dermatosis of end-stage renal disease: a possible association between abnormal porphyrin metabolism and aluminium.
    Gafter U; Mamet R; Korzets A; Malachi T; Schoenfeld N
    Nephrol Dial Transplant; 1996 Sep; 11(9):1787-91. PubMed ID: 8918623
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of medication in the level of aluminium in the blood of chronic haemodialysis patients.
    Bohrer D; Bertagnolli DC; de Oliveira SM; do Nascimento PC; de Carvalho LM; Garcia SC; Arantes LC; Barros EJ
    Nephrol Dial Transplant; 2009 Apr; 24(4):1277-81. PubMed ID: 19028749
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Desferrioxamine-induced changes of aluminium kinetics during haemodialysis.
    Graf H; Stummvoll HK; Meisinger V
    Proc Eur Dial Transplant Assoc; 1981; 18():674-80. PubMed ID: 7329995
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum aluminium in haemodialysis patients: relation to osteodystrophy, encephalopathy and aluminium hydroxide consumption.
    Heaf JG; Nielsen LP
    Miner Electrolyte Metab; 1984; 10(6):345-50. PubMed ID: 6503890
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The influence of aluminium on parathyroid hormone levels in haemodialysis patients.
    Cannata JB; Briggs JD; Junor BJ; Beastall G; Fell GS
    Proc Eur Dial Transplant Assoc; 1983; 19():244-7. PubMed ID: 6878239
    [TBL] [Abstract][Full Text] [Related]  

  • 33. What is the value of plasma/serum aluminum in patients with chronic renal failure?
    Winney RJ; Cowie JF; Robson JS
    Clin Nephrol; 1985; 24 Suppl 1():S2-8. PubMed ID: 3842104
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chronic renal failure and end-stage renal disease in northwest North Carolina. Importance of analgesic-associated nephropathy.
    Gonwa TA; Hamilton RW; Buckalew VM
    Arch Intern Med; 1981 Mar; 141(4):462-5. PubMed ID: 7212889
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Serum osteocalcin in children with chronic renal insufficiency].
    Peco-Antić A; Nastić-Mirić D; Milikić V; Babić D; Pejcić I; Kostić M; Paripović V; Jovanović O; Kruscić D; Mancić J
    Srp Arh Celok Lek; 1996; 124(9-10):227-31. PubMed ID: 9102853
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive value of serum aluminium levels for bone accumulation in haemodialyzed patients.
    Costantini S; Giordano R; Vernillo I; Piccioni A; Zapponi GA
    Ann Ist Super Sanita; 1989; 25(3):457-61. PubMed ID: 2624356
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NTP Toxicology and Carcinogenesis Studies of p-Nitrobenzoic Acid (CAS No. 62-23-7) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1994 Dec; 442():1-306. PubMed ID: 12595921
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Determination of the plasma aluminum concentration of hemodialysis patients].
    Kuleva V; Petrov I; Antonov S; Kiriakov Z
    Vutr Boles; 1984; 23(2):51-5. PubMed ID: 6741112
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of oral aluminium therapy on plasma aluminium levels in patients with chronic renal failure in an area with low water aluminium.
    Fleming LW; Stewart Wk; Fell GS; Halls DJ
    Clin Nephrol; 1982 May; 17(5):222-7. PubMed ID: 7094439
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hyperaluminemia in renal failure: the influence of age and citrate intake.
    Bakir AA; Hryhorczuk DO; Ahmed S; Hessl SM; Levy PS; Spengler R; Dunea G
    Clin Nephrol; 1989 Jan; 31(1):40-4. PubMed ID: 2914409
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.